OTCMKTS:PFHOD

Pacific Health Care Organization Competitors

$1.25
-2.85 (-69.51 %)
(As of 01/31/2020)
Add
Compare
Today's Range
$1.25
Now: $1.25
$1.25
50-Day Range
$1.25
MA: $1.25
$1.25
52-Week Range
$1.11
Now: $1.25
$5.90
Volume2,100 shs
Average Volume1,720 shs
Market Capitalization$16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Competitors

Pacific Health Care Organization (OTCMKTS:PFHOD) Vs. CLBS, BXRX, CCEL, GRNV, EMMA, and CTYX

Should you be buying PFHOD stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Pacific Health Care Organization, including Caladrius Biosciences (CLBS), Baudax Bio (BXRX), Cryo-Cell International (CCEL), GreenVision Acquisition (GRNV), Emmaus Life Sciences (EMMA), and Curative Biotechnology (CTYX).

Caladrius Biosciences (NASDAQ:CLBS) and Pacific Health Care Organization (OTCMKTS:PFHOD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Caladrius Biosciences and Pacific Health Care Organization, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Pacific Health Care Organization0000N/A

Caladrius Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 553.59%. Given Caladrius Biosciences' higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than Pacific Health Care Organization.

Earnings & Valuation

This table compares Caladrius Biosciences and Pacific Health Care Organization's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.81
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A

Pacific Health Care Organization has higher revenue and earnings than Caladrius Biosciences.

Risk and Volatility

Caladrius Biosciences has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Pacific Health Care Organization has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Caladrius Biosciences and Pacific Health Care Organization's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Pacific Health Care Organization16.87%14.47%12.96%

Institutional and Insider Ownership

9.0% of Caladrius Biosciences shares are held by institutional investors. 10.3% of Caladrius Biosciences shares are held by insiders. Comparatively, 61.6% of Pacific Health Care Organization shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Pacific Health Care Organization beats Caladrius Biosciences on 6 of the 10 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Pacific Health Care Organization and Baudax Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Baudax Bio00203.00

Baudax Bio has a consensus target price of $13.50, indicating a potential upside of 1,161.68%. Given Baudax Bio's higher probable upside, analysts plainly believe Baudax Bio is more favorable than Pacific Health Care Organization.

Earnings and Valuation

This table compares Pacific Health Care Organization and Baudax Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Pacific Health Care Organization has higher revenue and earnings than Baudax Bio.

Volatility and Risk

Pacific Health Care Organization has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500.

Profitability

This table compares Pacific Health Care Organization and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Baudax BioN/AN/AN/A

Institutional & Insider Ownership

7.9% of Baudax Bio shares are held by institutional investors. 61.6% of Pacific Health Care Organization shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pacific Health Care Organization beats Baudax Bio on 6 of the 10 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Pacific Health Care Organization and Cryo-Cell International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Cryo-Cell International0000N/A

Earnings and Valuation

This table compares Pacific Health Care Organization and Cryo-Cell International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Cryo-Cell International$31.80 million2.35$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Pacific Health Care Organization.

Volatility and Risk

Pacific Health Care Organization has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Profitability

This table compares Pacific Health Care Organization and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Cryo-Cell International10.39%-58.74%7.30%

Institutional & Insider Ownership

1.0% of Cryo-Cell International shares are held by institutional investors. 61.6% of Pacific Health Care Organization shares are held by company insiders. Comparatively, 53.8% of Cryo-Cell International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pacific Health Care Organization beats Cryo-Cell International on 6 of the 9 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Pacific Health Care Organization and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
GreenVision Acquisition0000N/A

Earnings and Valuation

This table compares Pacific Health Care Organization and GreenVision Acquisition's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
GreenVision AcquisitionN/AN/AN/AN/AN/A

Pacific Health Care Organization has higher revenue and earnings than GreenVision Acquisition.

Profitability

This table compares Pacific Health Care Organization and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
GreenVision AcquisitionN/AN/AN/A

Institutional & Insider Ownership

67.7% of GreenVision Acquisition shares are held by institutional investors. 61.6% of Pacific Health Care Organization shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pacific Health Care Organization beats GreenVision Acquisition on 5 of the 6 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Pacific Health Care Organization and Emmaus Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Emmaus Life Sciences0000N/A

Earnings and Valuation

This table compares Pacific Health Care Organization and Emmaus Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A

Pacific Health Care Organization has higher revenue and earnings than Emmaus Life Sciences.

Volatility and Risk

Pacific Health Care Organization has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500.

Profitability

This table compares Pacific Health Care Organization and Emmaus Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Emmaus Life SciencesN/AN/AN/A

Institutional & Insider Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. 61.6% of Pacific Health Care Organization shares are held by company insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pacific Health Care Organization beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Pacific Health Care Organization and Curative Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Curative BiotechnologyN/AN/AN/AN/AN/A

Pacific Health Care Organization has higher revenue and earnings than Curative Biotechnology.

Profitability

This table compares Pacific Health Care Organization and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Curative BiotechnologyN/AN/AN/A

Volatility & Risk

Pacific Health Care Organization has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Pacific Health Care Organization and Curative Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Curative Biotechnology0000N/A

Summary

Pacific Health Care Organization beats Curative Biotechnology on 5 of the 5 factors compared between the two stocks.


Pacific Health Care Organization Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.53-1.3%$91.03 millionN/A-2.39Decrease in Short Interest
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.07-0.9%$75.05 millionN/A-0.31Analyst Upgrade
Increase in Short Interest
News Coverage
Cryo-Cell International logo
CCEL
Cryo-Cell International
0.9$9.88-2.1%$74.80 million$31.80 million24.70High Trading Volume
GRNV
GreenVision Acquisition
0.3$10.18-0.1%$73.17 millionN/A0.00Increase in Short Interest
Emmaus Life Sciences logo
EMMA
Emmaus Life Sciences
0.2$1.30-0.0%$63.68 million$1.32 million0.00News Coverage
CTYX
Curative Biotechnology
0.0$0.12-16.5%$47.20 millionN/A0.00Decrease in Short Interest
Gap Down
BRTXQ
BioRestorative Therapies
0.0$0.01-0.0%$16.56 million$110,000.00-0.01Gap Down
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01-0.0%$16.56 million$110,000.000.00Decrease in Short Interest
Gap Down
PFHO
Pacific Health Care Organization
0.8$1.12-2.7%$14.27 million$7.33 million0.00
GNOW
American Caresource
0.7$0.01-0.0%$124,000.00N/A0.00Gap Down
HYBE
Hybrid Energy
0.0$0.00-0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
QMED
QMed
0.2$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.